OncoGynecologyNews.net

OncoGynecology Xagena

Xagena Mappa
Medical Meeting
Pneumobase.it
Neurobase.it

Abemaciclib ( Verzenios ) is an oral, selective cyclin-dependent kinase 4 & 6 inhibitor, approved for hormone receptor-positive ( HR+ ), human epidermal growth factor receptor 2-negative ( HER2- ) ...


The phase III MONALEESA-3 trial investigated Ribociclib, a cyclin-dependent kinase 4/6 ( CDK4/6 ) inhibitor, plus Fulvestrant as first-line ( 1L ) or second-line ( 2L ) treatment for postmenopausal p ...


The phase 3 KEYNOTE-522 trial investigating Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in combination with chemotherapy has met one of the dual-primary endpoints of pathological complete respon ...


A study has shown that women with specific DNA characteristics in certain areas of the genome may live longer if they take Aspirin [ Acetylsalicylic acid ] before they are diagnosed with breast cancer ...


The results for the pivotal phase II DESTINY-Breast01 trial of Trastuzumab deruxtecan ( DS-8201 ). The HER2-targeting antibody drug conjugate ( ADC ) was evaluated in patients with HER2-positive, un ...


Results of the global phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor Alpelisib ( BYL719 ) has met the primary endpoint showing an improvement in progression-free ...


Recurrent metastatic cervical cancer ( RMCC ), largely due to infections with high-risk types of human papillomavirus ( HPV ), remains an area of high unmet need for patients progressing after greater ...


PIK3CA mutations are common in breast cancer. The aim of a study was to evaluate the correlation of PIK3CA mutational status with pCR in patients with HER2-positive early breast cancer treated with ne ...


Among patients with HER2-positive, metastatic breast cancer that had progressed despite treatment with two or more forms of HER2-targeted therapy ( Trastuzumab [ Herceptin ] and Lapatinib [ Tykerb ] ) ...


Metastatic leiomyosarcomas of uterine or soft-tissue origin have poor prognosis and moderate chemosensitivity. Trabectedin has shown activity in pretreated leiomyosarcoma. Researchers did a single-g ...


Mammography screening may be effective in reducing breast cancer mortality in certain populations, but it can pose harm to women who participate. The limitations are best described as false-positives ...


The CHER-LOB randomized phase II study showed that the combination of Lapatinib ( Tyverb ) and Trastuzumab ( Herceptin ) plus chemotherapy increases the pathologic complete remission ( pCR ) rate comp ...


Alopecia is a common side-effect of chemotherapy and affects quality of life of cancer patients. Some patients and physicians believe that alopecia could be a surrogate marker for response to chemot ...


For a woman in the United States, the average lifetime risk of breast cancer is about 12.3%; the 10-year risks of invasive breast cancer at ages 40, 50, and 60 years are 1.5%, 2.3%, and 3.5% respectiv ...


The International Breast Cancer Study Group ( IBCSG ) has presented results of the randomized phase III SOFT trial at the 2014 San Antonio Breast Cancer Symposium. Suppression of Ovarian Function Tri ...